Skip to main content
SpringerLink
Log in
Book cover

Peripheral Arterial Disease pp 319–345Cite as

Large-Vessel Vasculitis

  • Chapter

  • 192 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Autoimmune inflammation of large-caliber arteries is an unusual cause of vascular insufficiency. Owing to its rarity, the diagnosis of large-vessel vasculitis (LVV) is often initially missed, leading to excess morbidity and mortality. Clues to the diagnosis of LVV include systemic signs of illness such as malaise, weight loss, or fever, with an unusual distribution of ischemic symptoms. Other cases are diagnosed serendipitously at the time of revascularization when inflammation is seen, leading to a search for the underlying cause and altering treatment for these patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hutchinson J. Diseases of the Arteries. Arch Surg 1890; 1: 323.

    Google Scholar 

  2. Harrison C. Giant-cell or temporal arteritis: a review. J Clin Pathol 1948;1:197–211. 3 Chakrabarty A, Franks AJ. Temporal artery biopsy: is there any value in examining biopsies at multiple levels? J Clin Pathol 2000; 53: 131–136.

    Google Scholar 

  3. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis: a population-based study. Ann Intern Med 1995; 122: 502–507.

    PubMed  CAS  Google Scholar 

  4. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999; 42: 311–317.

    Article  PubMed  CAS  Google Scholar 

  5. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998; 125: 521–526.

    Article  PubMed  CAS  Google Scholar 

  6. Poller DN, van Wyk Q, Jeffrey MJ. The importance of skip lesions in temporal arteritis. J Clin Pathol 2000; 53: 137–139.

    Article  PubMed  CAS  Google Scholar 

  7. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001; 30: 249–256.

    Article  PubMed  CAS  Google Scholar 

  8. Ostberg G. Temporal arteritis in a large necropsy series. Ann Rheum Dis 1971; 30: 224–235.

    Article  PubMed  CAS  Google Scholar 

  9. Nordborg E. Epidemiology of biopsy-positive giant cell arteritis: an overview. Clin Exp Rheumatol 2000; 18 (Suppl): S15–17.

    PubMed  CAS  Google Scholar 

  10. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–1128.

    Article  PubMed  CAS  Google Scholar 

  11. Baldursson O, Steinsson K, Bjornsson, J, Lie, JT. Giant cell arteritis in Iceland: an epidemiologic and histopathologic analysis. Arthritis Rheum 1994; 37: 1007–1012.

    Article  PubMed  CAS  Google Scholar 

  12. Smith CA, Fidler WJ, Pinals RS. The epidemiology of giant cell arteritis: report of a ten-year study in Shelby County, Tennessee. Arthritis Rheum 1983; 26: 1214–1219.

    Article  PubMed  CAS  Google Scholar 

  13. Bengtsson BA, Malmvall BE. The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica: incidences of different clinical presentations and eye complications. Arthritis Rheum 1981; 24: 899–904.

    Article  PubMed  CAS  Google Scholar 

  14. Boesen P, Sorensen SE. Giant cell arteritis, temporal arteritis, and polymyalgia rheumatica in a Danish county: a prospective investigation, 1982–1985. Arthritis Rheum 1987; 30: 294–299.

    Article  PubMed  CAS  Google Scholar 

  15. Sonnenblick M, Nesher G, Friedlander Y, Rubinow A. Giant cell arteritis in Jerusalem: a 12-year epidemiological study. Br J Rheumatol 1994; 33: 938–941.

    Article  PubMed  CAS  Google Scholar 

  16. Gonzalez E, Varnes WT, Lisse JR, Daniels JC, Hokanson JA. Giant-cell arteritis in the southern United States: an 11-year retrospective study from the Texas Gulf Coast. Arch Intern Med 1989; 149: 1561–1565.

    Article  PubMed  CAS  Google Scholar 

  17. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18: S9–11.

    Article  PubMed  CAS  Google Scholar 

  18. Hall S, Persellin S, Lie JT, O’Brien PC, Kurland LT, Hunder GG. The therapeutic impact of temporal artery biopsy. Lancet 1983; 2: 1217–1220.

    Article  PubMed  CAS  Google Scholar 

  19. Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21: 883–909.

    PubMed  CAS  Google Scholar 

  20. Lie J, Brown AL Jr, Carter ET. Spectrum of aging changes in temporal arteries. Its significance, in interpretation of biopsy of temporal artery. Arch Path Lab Med 1970; 90: 278–285.

    CAS  Google Scholar 

  21. Lie J. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21: 883–909.

    PubMed  CAS  Google Scholar 

  22. Esteban MJ, Font C, Hernandez-Rodriguez J, et al Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. Arthritis Rheum 2001; 44: 1387–1395.

    Article  PubMed  CAS  Google Scholar 

  23. Gabriel SE, O’Fallon WM, Achkar AA, Lie JT, Hunder GG. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol 1995; 22: 93–96.

    PubMed  CAS  Google Scholar 

  24. Chmelewski WL, McKnight KM, Agudelo CA, Wise CM. Presenting features and outcomes in patients undergoing temporal artery biopsy: a review of 98 patients. Arch Intern Med 1992; 152: 1690–1695.

    Article  PubMed  CAS  Google Scholar 

  25. Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987–992.

    PubMed  CAS  Google Scholar 

  26. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999; 42: 844–853.

    Article  PubMed  CAS  Google Scholar 

  27. Weyand CM, Goronzy JJ. Pathogenic principles in giant cell arteritis. Int J Cardiol 2000; 75 (Suppl 1): S9 - S15.

    Article  PubMed  Google Scholar 

  28. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41: 623–633.

    Article  PubMed  CAS  Google Scholar 

  29. Hunder G. Giant cell arteritis and polymyalgia rheumatica. Med Clin N Am 1997; 81: 195–219.

    Article  PubMed  CAS  Google Scholar 

  30. Salvarani C, Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999; 42: 1259–1266.

    Article  PubMed  CAS  Google Scholar 

  31. Ninet JP, Bachet P, Dumontet CM, Du Colombier PB, Stewart MD, Pasquier JH. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med 1990; 88: 13–20.

    Article  PubMed  CAS  Google Scholar 

  32. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83: 806–812.

    PubMed  CAS  Google Scholar 

  33. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111: 211–217.

    Article  PubMed  CAS  Google Scholar 

  34. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41: 1497–1504.

    Article  PubMed  CAS  Google Scholar 

  35. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000; 79: 283–292.

    Article  CAS  Google Scholar 

  36. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26–32.

    Article  PubMed  CAS  Google Scholar 

  37. Nesher G. Neurologic manifestations of giant cell arteritis. Clin Exp Rheumatol 2000; 18: S24–26.

    PubMed  CAS  Google Scholar 

  38. Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125: 509–520.

    Article  PubMed  CAS  Google Scholar 

  39. Myles AB. Steroid treatment in giant cell arteritis. Br J Rheumatol 1992; 31: 787.

    Article  PubMed  CAS  Google Scholar 

  40. Wilkinson IM, Russell RW. Arthritis of the head and neck in giant cell arteritis. Arch Neurol 1972; 27: 378–391.

    Article  PubMed  CAS  Google Scholar 

  41. Font C, Cid MC, Coll-Vinent B, Lopez-Soto A, Grau JM. Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 1997; 36: 251–254.

    Article  PubMed  CAS  Google Scholar 

  42. Le Hello C, Levesque H, Jeanton M, et al. Lower limb giant cell arteritis and temporal arteritis: followup of 8 cases. J Rheumatol 2001; 28: 1407–1412.

    PubMed  Google Scholar 

  43. Rasmussen TE, Hallett JW, Metzger RL, et al. Genetic risk factors in inflammatory abdominal aortic aneurysms: polymorphic residue 70 in the HLA-DR BI gene as a key genetic element. J Vasc Surg 1997; 25: 356–364.

    Article  PubMed  CAS  Google Scholar 

  44. Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 2001; 45: 140–5.

    Article  PubMed  CAS  Google Scholar 

  45. Kyle V, Cawston, TE, Hazleman, BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis 1989; 48: 667–671.

    Article  PubMed  CAS  Google Scholar 

  46. Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998; 125: 521–526.

    Article  PubMed  CAS  Google Scholar 

  47. Salvarani C, Macchioni P, Boiardi L, et al. Soluble interleukin 2 receptors in polymyalgia rheumatica/ giant cell arteritis: clinical and laboratory correlations. J Rheumatol 1992; 19: 1100–1106.

    PubMed  CAS  Google Scholar 

  48. Salvarani C, Boiardi L, Macchioni P, et al. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1995; 54: 640–644.

    Article  PubMed  CAS  Google Scholar 

  49. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041–1048.

    Article  PubMed  CAS  Google Scholar 

  50. Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47: 733–739.

    Article  PubMed  CAS  Google Scholar 

  51. Nesher G, Rubinow A, Sonnenblick M. Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study. Clin Exp Rheumatol 1997; 15: 3033–306.

    Google Scholar 

  52. Lundberg I, Hedfors E. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1990; 17: 1340–1345.

    PubMed  CAS  Google Scholar 

  53. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis 1989; 48: 658–661.

    Article  PubMed  CAS  Google Scholar 

  54. Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975; 82: 613–618.

    PubMed  CAS  Google Scholar 

  55. Hayreh SS. Steroid therapy for visual loss in patients with giant-cell arteritis. Lancet 2000; 355: 1572–1573.

    Article  PubMed  CAS  Google Scholar 

  56. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136–138.

    Article  PubMed  Google Scholar 

  57. Doury P, Pattin S, Eulry F, Thabaut A. The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1983; 26: 689–690.

    Article  PubMed  CAS  Google Scholar 

  58. de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992; 232: 373–375.

    PubMed  Google Scholar 

  59. Schaufelberger C, Andersson R, Nordborg E. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 1998; 37: 464–5.

    Article  PubMed  CAS  Google Scholar 

  60. Jover JH-G, C. Morado, IC. Vargas, E. Banares, A. Fernandez-Gutierrez, B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106–114.

    PubMed  CAS  Google Scholar 

  61. Hoffman G, Cid M, Hellmann D, et al. A multicenter, randomized, double-blind, placebo-controlled study of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum, in press.

    Google Scholar 

  62. Numano F, Kakuta T. Takayasu arteritis: five doctors in the history of Takayasu arteritis. Int J Cardiol 1996; 54 (Suppl): S1–10.

    PubMed  Google Scholar 

  63. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu’s arteritis. Lancet 2000; 356: 1023–1025.

    Article  PubMed  CAS  Google Scholar 

  64. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919–929.

    PubMed  CAS  Google Scholar 

  65. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129–1134.

    Article  PubMed  CAS  Google Scholar 

  66. Sharma BK, Jain S, Radotra BD. An autopsy study of Takayasu arteritis in India. Int J Cardiol 1998; 66 (Suppl 1): S85–90.

    Article  PubMed  Google Scholar 

  67. Gravanis M. Giant cell arteritis and Takayasu aortitis: morphologic, pathogenetic and etiologic factors. Int J Cardiol 2000; 75 (Suppl 1): S21–33.

    Article  PubMed  Google Scholar 

  68. Lupi-Herrera E, Sanchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu’s arteritis: clinical study of 107 cases. Am Heart J 1977; 93: 94–103.

    Article  PubMed  CAS  Google Scholar 

  69. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55–60.

    Article  PubMed  CAS  Google Scholar 

  70. Seko Y. Takayasu arteritis: insights into immunopathology. Jpn Heart J 2000; 41: 15–26.

    Article  PubMed  CAS  Google Scholar 

  71. Nakao K, Ikeda M, Kimata S, Niitani H, Niyahara M. Takayasu’s arteritis: clinical report of eighty-four cases and immunological studies of seven cases. Circulation 1967; 35: 1141–1155.

    Article  PubMed  CAS  Google Scholar 

  72. Canas CA, Jimenez CA, Ramirez LA, et al. Takayasu arteritis in Colombia. Int J Cardiol 1998; 66 (Suppl 1): S73–79.

    Article  PubMed  Google Scholar 

  73. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder GG. Takayasu arteritis: a study of 32 North American patients. Medicine (Baltimore) 1985; 64: 89–99.

    CAS  Google Scholar 

  74. Deyu Z, Guozhang L. Clinical study of aortic regurgitation with aortoarteritis. Int J Cardiol 2000; 75(Suppll):Sl41–5145.

    Google Scholar 

  75. Lie JT. Pathology of isolated nonclassical and catastrophic manifestations of Takayasu arteritis. Int J Cardiol 1998; 66 (Suppl 1): S11–21.

    Article  PubMed  Google Scholar 

  76. Kihara M, Kimura K, Yakuwa H, et al. Isolated left coronary ostial stenosis as the sole arterial involvement in Takayasu’s disease. J Intern Med 1992; 232: 353–355.

    Article  PubMed  CAS  Google Scholar 

  77. Amano J, Suzuki A. Coronary artery involvement in Takayasu’s arteritis: collective review and guideline for surgical treatment. J Thorac Cardiovasc Surg 1991; 102: 554–560.

    PubMed  CAS  Google Scholar 

  78. Kiyosawa M, Baba T. Ophthalmological findings in patients with Takayasu disease. Int J Cardiol 1998; 66 (Suppl l): S141–147.

    Article  PubMed  Google Scholar 

  79. Baltazares M, Mendoza F, Dabague J, Reyes PA. Antiaorta antibodies and Takayasu arteritis. Int J Cardiol 1998;66(Suppl 1):S183–187; discussion S189.

    Google Scholar 

  80. Tanigawa K, Eguchi K, Kitamura Y, et al. Magnetic resonance imaging detection of aortic and pulmonary artery wall thickening in the acute stage of Takayasu arteritis: improvement of clinical and radiologic findings after steroid therapy. Arthritis Rheum 1992; 35: 476–480.

    Article  PubMed  CAS  Google Scholar 

  81. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS. Treatment of glucocorticoidresistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578–582.

    Article  PubMed  CAS  Google Scholar 

  82. Daina E, Schieppati A, Remuzzi G. Mycophenolate mofetil for the treatment of Takayasu arteritis: report of three cases. Ann Intern Med 1999; 130: 422–426.

    PubMed  CAS  Google Scholar 

  83. Hoffman G. Treatment of resistant Takayasu’s arteritis. Rheum Dis Clin N Am 1995; 21: 73–80.

    CAS  Google Scholar 

  84. Moncada GA, Hashimoto Y, Kobayashi Y, Maruyama Y, Numano F. Usefulness of beta blocker therapy in patients with Takayasu arteritis and moderate or severe aortic regurgitation. Jpn Heart J 2000; 41: 325–337.

    Article  PubMed  CAS  Google Scholar 

  85. Hashimoto Y, Tanaka M, Hata A, Kakuta T, Maruyama Y, Numano E Four years follow-up study in patients with Takayasu arteritis and severe aortic regurgitation; assessment by echocardiography. Int J Cardiol 1996; 54 (Suppl): S 173–176.

    Google Scholar 

  86. Fava MP, Foradori GB, Garcia CB, et al. Percutaneous transluminal angioplasty in patients with Takayasu arteritis: five-year experience. J Vasc Intery Radiol 1993; 4: 649–52.

    Article  CAS  Google Scholar 

  87. Joseph S, Mandalam KR, Rao VR, et al. Percutaneous transluminal angioplasty of the subclavian artery in nonspecific aortoarteritis: results of long-term follow-up. J Vasc Intery Radiol 1994; 5: 573–580.

    Article  CAS  Google Scholar 

  88. Sharma BK, Jain S, Bali HK, Jain A, Kumari S. A follow-up study of balloon angioplasty and de-novo stenting in Takayasu arteritis. Int J Cardiol 2000; 75 (Suppl 1): S147–152.

    Article  PubMed  Google Scholar 

  89. Ishikawa K, Maetani S. Peripheral arterial and aortic diseases: long-term outcome for 120 Japanese patients with Takayasu’s disease: clinical and statistical analyses of related prognostic factors. Circulation 1994; 90: 1855–1860.

    Article  PubMed  CAS  Google Scholar 

  90. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet’s disease. N Engl J Med 1999; 341: 1284–1291.

    Article  PubMed  CAS  Google Scholar 

  91. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet’s disease. J Rheumatol 1992; 19: 402–410.

    PubMed  CAS  Google Scholar 

  92. Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behcet’s disease. A study in 25 patients. J Rheumatol 1995; 22: 2103–2113.

    Google Scholar 

  93. Hamza M. Large artery involvement in Behcet’s disease. J Rheumatol 1987; 14: 554–559.

    PubMed  CAS  Google Scholar 

  94. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet’s syndrome. Arthritis Rheum 2001; 44: 2686–2692.

    Article  PubMed  CAS  Google Scholar 

  95. Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EE. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet’s disease. J Am Acad Dermatol 1991; 24: 973–978.

    Article  PubMed  CAS  Google Scholar 

  96. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 443–450.

    PubMed  CAS  Google Scholar 

  97. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40: 769–774.

    Article  PubMed  CAS  Google Scholar 

  98. Sullu Y, Oge I, Erkan D, Ariturk N, Mohajeri E Cyclosporin-A therapy in severe uveitis of Behcet’s disease. Acta Ophthalmol Scand 1998; 76: 96–99.

    Article  PubMed  CAS  Google Scholar 

  99. Smulders FM, Oosterhuis JA. Treatment of Behcet’s disease with chlorambucil. Ophthalmologica 1975; 171: 347–352.

    Article  PubMed  CAS  Google Scholar 

  100. McAdam LP, O’Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55: 193–215.

    Article  CAS  Google Scholar 

  101. Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med 1998;129:114–122. 1 03. Cipriano PR, Alonso DR, Baltaxe HA, Gay WA, Jr, Smith JP. Multiple aortic aneurysms in relapsing polychondritis. Am J Cardiol 1976; 37: 1097–1102.

    Article  Google Scholar 

  102. Michet CJ, Jr, McKenna CH, Luthra HS, O’Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986; 104: 74–78.

    PubMed  Google Scholar 

  103. Esdaile J, Hawkins D, Gold P, Freedman SO, Duguid WP. Vascular involvement in relapsing polychondritis. Can Med Assoc J 1977; 116: 1019–1022.

    PubMed  CAS  Google Scholar 

  104. Stewart SR, Robbins DL, Castles JJ. Acute fulminant aortic and mitral insufficiency in ankylosing spondylitis. N Engl J Med 1978; 299: 1448–1449.

    Article  PubMed  CAS  Google Scholar 

  105. Bulkley BH, Roberts WC. Ankylosing spondylitis and aortic regurgitation: description of the characteristic cardiovascular lesion from study of eight necropsy patients. Circulation 1973; 48: 1014–1027.

    Article  PubMed  CAS  Google Scholar 

  106. Ansell BB, Bywaters EGL, Doniach, I. The aortic lesion of ankylosing spondylitis. Br Heart J 1958; 20: 507.

    Article  PubMed  CAS  Google Scholar 

  107. Arnason JA, Patel AK, Rahko PS, Sundstrom WR. Transthoracic and transesophageal echocardiographic evaluation of the aortic root and subvalvular structures in ankylosing spondylitis. J Rheumatol 1996; 23: 120–123.

    PubMed  CAS  Google Scholar 

  108. O’Neill TW, Bresnihan B. The heart in ankylosing spondylitis. Ann Rheum Dis 1992; 51: 705–706.

    Article  PubMed  Google Scholar 

  109. Davidson PB, Baggenstoss AH, Slocumb CH, Daugherty GW. Cardiac and aortic lesions in rheumatoid spondylitis. Mayo Clin Proc 1963; 36: 427–435.

    Google Scholar 

  110. Bergfeldt L, Insulander P, Lindblom D, Moller E, Edhag O. HLA-B27: an important genetic risk factor for lone aortic regurgitation and severe conduction system abnormalities. Am J Med 1988; 85: 12–18.

    Article  PubMed  CAS  Google Scholar 

  111. Townend JN, Emery P, Davies MK, Littler WA. Acute aortitis and aortic incompetence due to systemic rheumatological disorders. Int J Cardiol 1991; 33: 253–258.

    Article  PubMed  CAS  Google Scholar 

  112. Park JH, Chung JW, Im JG, Kim SK, Park YB, Han MC. Takayasu arteritis: evaluation of mural changes in the aorta and pulmonary artery with CT angiography. Radiology 1995; 196: 89–93.

    PubMed  CAS  Google Scholar 

  113. Miller JH, Gunarta H, Stanley P. Gallium scintigraphic demonstration of arteritis in Takayasu disease. Clin Nucl Med 1996; 21: 882–883.

    Article  PubMed  CAS  Google Scholar 

  114. Hoffmann M, Corr P, Robbs J. Cerebrovascular findings in Takayasu disease. J Neuroimaging 2000; 10: 84–90.

    PubMed  CAS  Google Scholar 

  115. Stanson AW, Klein RG, Hunder GG. Extracranial angiographic findings in giant cell (temporal) arteritis. Am J Roentgenol 1976; 127: 957–963.

    CAS  Google Scholar 

  116. Cantu C, Pineda C, Barinagarrementeria F, et al. Noninvasive cerebrovascular assessment of Takayasu arteritis. Stroke 2000; 31: 2197–2202.

    Article  PubMed  CAS  Google Scholar 

  117. Atalay MK, Bluemke DA. Magnetic resonance imaging of large vessel vasculitis. Curr Opin Rheumatol 2001; 13: 41–47.

    Article  PubMed  CAS  Google Scholar 

  118. Choe YH, Kim DK, Koh EM, Do YS, Lee WR. Takayasu arteritis: diagnosis with MR imaging and MR angiography in acute and chronic active stages. J Magn Reson Imaging 1999; 10: 751–757.

    Article  PubMed  CAS  Google Scholar 

  119. Park SH, Chung JW, Lee JW, Han MH, Park JH. Carotid artery involvement in Takayasu’s arteritis: evaluation of the activity by ultrasonography. J Ultrasound Med 2001; 20: 371–378.

    PubMed  CAS  Google Scholar 

  120. Schmidt WA, Kraft HE, Borkowski A, Gromnica-Ihle EJ. Color duplex ultrasonography in large-vessel giant cell arteritis. Scand J Rheumatol 1999; 28: 374–376.

    Article  PubMed  CAS  Google Scholar 

  121. Schmidt WA. Doppler ultrasonography in the diagnosis of giant cell arteritis. Clin Exp Rheumatol 2000; 18 (Suppl 20): S40–42.

    PubMed  CAS  Google Scholar 

  122. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336–1342.

    Article  PubMed  CAS  Google Scholar 

  123. Sun Y, Yip PK, Jeng JS, Hwang BS, Lin WH. Ultrasonographic study and long-term follow-up of Takayasu’s arteritis. Stroke 1996;27:2178–21s82.

    Google Scholar 

Download references

Authors
  1. Eugene Y. Kissin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter A. Merkel MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, Boston University Medical Center, Boston, MA, USA

    Jay D. Coffman MD  & Robert T. Eberhardt MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kissin, E.Y., Merkel, P.A. (2003). Large-Vessel Vasculitis. In: Coffman, J.D., Eberhardt, R.T. (eds) Peripheral Arterial Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-331-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-331-6_19

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-326-8

  • Online ISBN: 978-1-59259-331-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation